We are a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. Our product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.
Our goal is to be a leader in developing and commercializing specialized, targeted, plasma-derived therapeutics to extend and enhance the lives of individuals who are naturally or medically immune-compromised.
ADMA also operates ADMA BioCenters, a FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacture of the Company's lead product candidate RI-002.
465 Route 17 South
Ramsey, NJ 07446
Pharmaceutical Preparation Manufacturing (325412)
Biological Products, Except Diagnostic Substances (2836)